Utilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based study

Authors

Daniel R. Morales (ORCID: https://orcid.org/0000-0002-0063-8069)
Geert Molenberghs (ORCID: https://orcid.org/0000-0002-6453-5448)
Niel Hens (ORCID: https://orcid.org/0000-0003-1881-0637)
Jonas Crèvecoeur (ORCID: https://orcid.org/0000-0002-2983-8857)
Xavier Kurz (ORCID: https://orcid.org/0000-0002-9838-7754)
Chantal Quinten (ORCID: https://orcid.org/0000-0003-2691-2326)
Johan Verbeeck (ORCID: https://orcid.org/0000-0002-4923-1032)
Lander Willem (ORCID: https://orcid.org/0000-0002-9210-1196)
Steven Abrams (ORCID: https://orcid.org/0000-0001-7353-9304)
Neilshan Loedy (ORCID: https://orcid.org/0000-0002-4252-1061)
Catherine Cohet (ORCID: https://orcid.org/0000-0002-0022-7251)
Hector Gonzalez Dorta (ORCID: https://orcid.org/0009-0005-6277-4890)